Working… Menu

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03884829
Recruitment Status : Unknown
Verified October 2018 by Cyclacel Pharmaceuticals, Inc..
Recruitment status was:  Recruiting
First Posted : March 21, 2019
Last Update Posted : April 5, 2019
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
Cyclacel Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : October 26, 2020
Estimated Study Completion Date : February 28, 2021